AI specialist Recursion trims pipeline in latest shakeup
The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote in a note to investors.
The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote in a note to investors.
